Literature DB >> 31207119

Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats.

Daisuke Gotoh1, Kazumasa Torimoto1, Hirotaka Iwasaki2, Takashi Iwamoto1, Yosuke Morizawa1, Shunta Hori1, Makito Miyake1, Nobumichi Tanaka1, Akihide Hirayama3, Eiichiro Nishi2, Kiyohide Fujimoto1.   

Abstract

OBJECTIVE: This study investigated the effects of tadalafil on the urethra and detrusor in the initial phase of diabetes in rats.
METHODS: Thirty-six female Sprague-Dawley rats were assigned to a non-diabetes (ND), diabetes (D), or tadalafil-treated diabetes (DT) group (n = 12 per group), with the DT group receiving oral tadalafil (2 mg/kg/d) for 7 days before the experiments. Seven weeks after diabetes induction (by a single intraperitoneal injection of streptozotocin), urethral and intravesical pressure were simultaneously recorded in vivo, whereas responses of detrusor strips to potassium chloride (30 mM), electrical field stimulation (EFS) and carbachol were measured in vitro.
RESULTS: The intravesical pressure at which the urethra started to relax was significantly lower in the DT than D group (mean [± s.d.] 18.9 ± 2.9 vs 29.1 ± 6.6 cm H2 O; P < .05). In addition, the reduction in urethral pressure was significantly larger in the DT than D group (-10.9 ± 4.0 vs -4.0 ± 2.9 cm H2 O; P < .05). Detrusor stimulation revealed that the mean contractile responses to EFS and carbachol were significantly lower in the ND and DT groups than in the D group (120.7 ± 26.5% and 130.8 ± 15.8% vs 200.1 ± 47.9% of the 30 mM KCl-induced contraction, respectively, in response to 50 Hz EFS [P < .05]; 211.1 ± 35.4% and 208.4 ± 25.3% vs 425.7 ± 125.0% of the 30 mM KCl-induced contraction, respectively, in response to 10-3 M carbachol [P < .05]).
CONCLUSIONS: Tadalafil restored urethral relaxation function and detrusor responses to EFS and carbachol during the initial phase of diabetes.
© 2019 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  detrusor; diabetes; phosphodiesterase 5; rat; tadalafil; urethra

Mesh:

Substances:

Year:  2019        PMID: 31207119     DOI: 10.1111/luts.12272

Source DB:  PubMed          Journal:  Low Urin Tract Symptoms        ISSN: 1757-5664            Impact factor:   1.592


  2 in total

Review 1.  Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.

Authors:  Betül R Erdogan; Guiming Liu; Ebru Arioglu-Inan; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-12       Impact factor: 3.195

2.  Pathophysiological changes of the lower urinary tract behind voiding dysfunction in streptozotocin-induced long-term diabetic rats.

Authors:  Kazuki Masuda; Naoki Aizawa; Daiji Watanabe; Takatsugu Okegawa; Haruki Kume; Yasuhiko Igawa; Hiroshi Fukuhara
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.